ReviewBlood2018
How and when I do allogeneic transplant in CLL.
Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 58 citations in OpenAlex.
- Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.Blood advances · 2022Trial
- BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.Blood · 2021Trial
- Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.Internal medicine journal · 2026Article
- Is CLL curable?HemaSphere · 2026Article
- Review
- Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era.Internal medicine journal · 2025Article
- CD38 prognostic role in chronic lymphocytic leukemia patients treated with standard chemotherapy or targeted agents: a monocentric real-life experience.Frontiers in oncology · 2025Article
- The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab.Cancers · 2024Article
- Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.Blood advances · 2023Article
- Review
- Review
- Management of relapsed/refractory Chronic Lymphocytic Leukemia.American journal of hematology · 2022Review
- Targeted Drug Delivery for Chronic Lymphocytic Leukemia.Pharmaceutical research · 2022Review
- Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia.Scientific reports · 2022Article
- The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review.Frontiers in oncology · 2022Review
- Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia.Frontiers in oncology · 2022Review
- The potential of pirtobrutinib in multiple B-cell malignancies.Therapeutic advances in hematology · 2022Review
- Prognostic significance of microRNA 17-92 cluster expression in Egyptian chronic lymphocytic leukemia patients.Journal of the Egyptian National Cancer Institute · 2021Article
- Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.Blood advances · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.